Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound having the formula I, or a pharmaceutically acceptable salt thereof,



(I)

wherein

Y is -NH-R^2 or a group of formula



,

R^1 is cycloalkyl or non-substituted alkyl,

R^2 is cycloalkyl,

R^3 is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino,

~~or R^2R^3 is an alkylene bridging group,~~

R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, alkyl or halogen,

or R^aR^b is carbonyl,

R^4 is hydrogen or alkyl,

R^5 is cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that ~~when Y is -NHR^2 and R^{2}R^3 is an alkylene bridging group or~~ when Y is a group of formula



,

R^1 is a cycloalkyl.

2. (Original) A compound according to claim 1 wherein Y is -NH-R^2.

3. (Currently Amended) A compound according to claim 2 wherein

R^1 is C3-7-cycloalkyl or non-substituted alkyl,

R^2 is C3-7-cycloalkyl,

R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,

~~or R^{2}R^3 is a C2-4-alkylene bridging group,~~

R^4 is hydrogen or C1-4-alkyl,

R^5 is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

4. (Currently Amended) A compound according to claim 2 wherein R^1 is C3-4-alkyl or C3-5-cycloalkyl~~, preferably cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl or cyclopropylmethyl~~.

5. (Currently Amended) A compound according to claim 2 wherein

R^2 is a C3-4-non-substituted cycloalkyl, or a cycloalkyl substituted by a C1-6-alkyl or an aryl, ~~preferably cyclopropyl or cyclobutyl,~~

and/or R^3 is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy~~,~~

~~or R^{2}R^3 is an alkylene bridging group selected from ethylene, propylene and butylene~~.

6. (Currently Amended)A compound according to claim 2 wherein

R^4 is hydrogen or C1-4-alkyl~~, preferably hydrogen or methyl~~,

and/or R^5 is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfanyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-

nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl,

or NR^4R^5 is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-carbamoyl-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-methyl-1-piperidinyl, 4-hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-oxo-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.

7. (Previously Presented) A compound selected from
6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine;
N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidin-amine;
N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine;
6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine;
N,2-dicyclo-propyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; and
pharmaceutically acceptable salts thereof.

8. (Original) A compound according to claim 1 wherein Y is a group of formula



.

9. (Currently Amended) A compound according to claim 8 wherein NR^4R^5 is a 5- to 9-membered heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom~~, preferably 1-azepanyl~~.

10. (Original) A compound according to claim 9 wherein

R^1 is C3-7-cycloalkyl,

R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,

R^a is hydrogen, C1-4-alkyl, C2-6-alkenyl, C2-6-alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, C1-4-alkyl or halogen,

or R^aR^b is carbonyl.

11. (Currently Amended) A compound according to claim 10 wherein R^1 is C3-4-cycloalkyl~~, preferably cyclopropyl~~.

12. (Currently Amended) A compound according to claims 10 wherein R^3 is hydrogen or C1-4-alkyl~~, preferably hydrogen or methyl~~.

13. (Currently Amended) A compound according to claim 10 wherein

R^a is hydrogen, methyl, hydroxy, methoxy, methylsulfonyloxy, a Br atom, a F atom or cyano, ~~preferably, hydrogen, methyl, hydroxy or a F atom,~~

and/or R^b is hydrogen or methyl, ~~preferably hydrogen,~~

or R^aR^b is carbonyl.

14. (Previously Presented) A compound selected from

1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane;

1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane; and

pharmaceutically acceptable salts thereof.

15. (Previously Presented) A compound according to claim 1 as a pure enantiomer.

16. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.

17. (Original) A pharmaceutical composition according to claim 16 for administration by inhalation.

18-19. (Canceled)

20. (Currently Amended) A method for treating ~~respiratory disorders in connection with~~ Chronic Obstructive Pulmonary Disease ~~or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma~~ comprising administering a therapeutically effective amount of at least one compound according to claim 1 or a pharmaceutically acceptable salt thereof to a patient.

21-25. (Canceled)

26. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound according to claim **7** in combination with a pharmaceutically acceptable diluent or carrier.

27. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound according to claim 14 in combination with a pharmaceutically acceptable diluent or ~~canier~~carrier.

28. (Previously Presented) A compound according to claim 7 as a pure enantiomer.

29. (Previously Presented) A compound according to claim 14 as a pure enantiomer.

30. (Previously Presented) A pharmaceutical composition according to claim 26 for administration by inhalation.

31. (Previously Presented) A pharmaceutical composition according to claim 27 for administration by inhalation.

32. (Currently Amended) A method for treating ~~respiratory disorders in connection with~~ Chronic Obstructive Pulmonary Disease ~~or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma~~ comprising administering a therapeutically effective amount of at least one compound according to claim 7 or a pharmaceutically acceptable salt thereof to a patient.

33. (Currently Amended) A method for treating ~~respiratory disorders in connection with~~ Chronic Obstructive Pulmonary Disease ~~or for treating symptoms related to chronic~~

~~bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma~~ comprising administering a therapeutically effective amount of at least one compound according to claim 14 or a pharmaceutically acceptable salt thereof to a patient.

34. (New) A compound according to claim 4 wherein R^1 is cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl or cyclopropylmethyl.

35. (New) A compound according to claim 5 wherein R^2 is cyclopropyl or cyclobutyl.

36. (New) A compound according to claim 6 wherein R^4 is hydrogen or methyl.

37. (New) A compound according to claim 9 wherein NR^4R^5 is 1-azepanyl, which may be substituted.

38. (New) A compound according to claim 11 wherein R^1 is cyclopropyl.

39. (New) A compound according to claims 12 wherein R^3 is hydrogen or methyl.

40. (New) A compound according to claim 13 wherein R^a is hydrogen, methyl, hydroxy or a F atom, and/or R^b is hydrogen.